Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company focusing on rare disease treatments, has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Jonathan Guarino, Senior VP and CFO, will present at 9:00 AM ET. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. Company management will be available for one-on-one investor meetings throughout the day.
Soligenix (Nasdaq: SNGX), una società biofarmaceutica in fase avanzata che si concentra sui trattamenti per malattie rare, ha annunciato la sua partecipazione alla ThinkEquity Conference il 30 ottobre 2024, presso il Mandarin Oriental Hotel di New York. Jonathan Guarino, Vicepresidente Senior e CFO, presenterà alle 9:00 AM ET. La conferenza riunisce investitori istituzionali, clienti aziendali e professionisti del settore per presentare innovazioni e strategie finanziarie. La direzione dell'azienda sarà disponibile per incontri individuali con gli investitori per tutto il giorno.
Soligenix (Nasdaq: SNGX), una empresa biofarmacéutica en etapa avanzada enfocada en tratamientos para enfermedades raras, ha anunciado su participación en la ThinkEquity Conference el 30 de octubre de 2024, en el Mandarin Oriental Hotel de Nueva York. Jonathan Guarino, VP Senior y CFO, presentará a las 9:00 AM ET. La conferencia reúne a inversores institucionales, clientes corporativos y profesionales de la industria para mostrar innovaciones y estrategias financieras. La dirección de la empresa estará disponible para reuniones individuales con inversores durante todo el día.
솔리젠닉스 (Nasdaq: SNGX), 희귀 질환 치료에 주력하는 후기 단계의 생명공학 회사,는 2024년 10월 30일 뉴욕 만다린 오리엔탈 호텔에서 열리는 ThinkEquity Conference에 참여한다고 발표했습니다. 조나단 과리노, 수석 부사장 겸 CFO가 오전 9시(동부 시간)에 발표할 예정입니다. 이 컨퍼런스는 기관 투자자, 기업 고객 및 업계 전문가들을 한자리에 모아 혁신과 재무 전략을 선보입니다. 회사 관리팀은 하루 종일 투자자와의 일대일 회의에 참석할 예정입니다.
Soligenix (Nasdaq: SNGX), une société biopharmaceutique en phase avancée axée sur les traitements des maladies rares, a annoncé sa participation à la ThinkEquity Conference le 30 octobre 2024, à l'Hôtel Mandarin Oriental à New York. Jonathan Guarino, Vice-Président Senior et CFO, présentera à 9h00 ET. La conférence réunit des investisseurs institutionnels, des clients d'entreprise et des professionnels de l'industrie pour mettre en avant des innovations et des stratégies financières. La direction de l'entreprise sera disponible tout au long de la journée pour des réunions individuelles avec les investisseurs.
Soligenix (Nasdaq: SNGX), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Behandlung seltener Krankheiten konzentriert, hat seine Teilnahme an der ThinkEquity Conference am 30. Oktober 2024 im Mandarin Oriental Hotel in New York bekannt gegeben. Jonathan Guarino, Senior VP und CFO, wird um 9:00 Uhr ET präsentieren. Die Konferenz bringt institutionelle Investoren, Unternehmenskunden und Branchenfachleute zusammen, um Innovationen und Finanzstrategien zu präsentieren. Das Management des Unternehmens wird den ganzen Tag über für persönliche Gespräche mit Investoren zur Verfügung stehen.
- None.
- None.
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief Financial Officer of Soligenix, will be presenting at 9:00 AM ET on October 30th. Members of Soligenix management will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here.
About ThinkEquity
ThinkEquity is a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company’s website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Soligenix, Inc. Contact Information
Jonathan Guarino, CPA, CGMA
Senior Vice President and Chief Financial Officer
(609) 538-8200 | www.soligenix.com
Soligenix, Inc.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540
FAQ
When is Soligenix (SNGX) presenting at the 2024 ThinkEquity Conference?
Where will the 2024 ThinkEquity Conference featuring Soligenix (SNGX) be held?
Who will be presenting for Soligenix (SNGX) at the 2024 ThinkEquity Conference?